Murad Gezer

Dr. Murad Gezer

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2024 in Journal of Perinatal Medicine
Verified
Journal Article
Closed access
ODOya Demirci
Oya Demirci
MGMurad Gezer
Murad Gezer
ÖTÖykü Tosun
Öykü Tosun
Objectives: To assess congenital fetal bradyarrhythmias with regard to etiological causes, features, risk factors, and prognosis. Methods: This retrospective study involved fetuses with fetal bradyarrhythmias. All fetuses were evaluated by ultrasonography. Parental ECGs and family histories were obtained, and maternal autoantibodies were measured. Gestational age at diagnosis, fetal atrial and ventricular rates at presentation, type of bradyarrhythmias, the presence or absence of a congenital heart defect (CHD), fetal hydrops, fetal myocardial dysfunction, extra-cardiac abnormalities, maternal autoimmune diseases, maternal autoantibodies as well as prenatal treatment, and neonatal outcome were collected. Results: Of the 40 fetuses included in the study, 11 had maternal rheumatologic disease, 16 had complex cardiac anomalies such as left and right isomerism. Fetuses with CHD significantly differed from those without CHD with increased rates of extra-cardiac anomalies, hydrops, fetal deaths and shorter survival after 28 days (p<0.05). Survival was significantly better in fetuses with maternal rheumatic disease as compared with those with no maternal rheumatic disease (p<0.05). Maternal anti-arrhythmic therapy was administered in 11 fetuses. In utero maternal treatment resulted in no significant difference in the course of arrhythmia or hydrops in fetuses with or without maternal rheumatic disease (p<0.05). In regression analysis, the absence of fetal hydrops was the only independent factor associated with survival (p=0.04). Conclusions: The course of bradyarrhythmias, along with survival, seems to be more favorable in fetuses with maternal rheumatic disease than in those with CHD, especially left and right isomerism. Hydrops was the sole independent factor associated with poor survival.

28 July 2025 in Journal of Perinatal Medicine
Verified
Journal Article
Open access
PDF file
MGMurad Gezer
Murad Gezer
ÜTÜmit Taşdemir
Ümit Taşdemir
MÖMucize Eriç Özdemir
Mucize Eriç Özdemir
SYSevdenur Yiğit
Sevdenur Yiğit
BCBüşra Cambaztepe
Büşra Cambaztepe
ODOya Demirci
Oya Demirci
Objectives: This study aimed to compare noninvasive liver fibrosis markers, including the Aspartate Aminotransferase Platelet Ratio Index (APRI) and FIB-4, between patients with hypertensive disorders of pregnancy (HDP) and healthy controls and to investigate the association between these markers and adverse maternal and perinatal outcomes. Methods: In this retrospective case-control study, 205 patients with HDP and 192 normotensive controls were included for evaluation. Demographic data, laboratory findings, and maternal and perinatal outcomes were compared. FIB-4 and APRI scores were calculated using second-trimester AST, ALT, and platelet levels. ROC curve analysis was used to assess the predictive accuracy of these indices for HELLP syndrome and other complications. Linear regression analysis was applied to evaluate the parameters associated with the FIB-4 score. Results: FIB-4 and APRI scores were significantly higher in patients with HDP compared to controls (p<0.05). Among patients with severe preeclampsia and HELLP syndrome, fibrosis scores were markedly elevated. FIB-4 and APRI showed excellent diagnostic performance for HELLP syndrome (AUC: 0.976 and 0.992, respectively), with optimal cutoffs of 1.52 and 0.7. However, their predictive role for general adverse maternal and perinatal outcomes was limited. In multivariate regression, systolic blood pressure, maternal age, and adverse maternal outcomes were independent predictors of increased FIB-4 scores (p<0.05). Conclusions: FIB-4 and APRI may be considered simple, noninvasive indices that could contribute to early risk stratification for HELLP syndrome among patients with HDP. Although their predictive capacity remains to be validated in larger prospective studies, they may offer preliminary insights into hepatic dysfunction during pregnancy.

13 June 2024 in Journal of Gynecology Obstetrics and Human Reproduction
Verified
Journal Article
Closed access
MGMurad Gezer
Murad Gezer
ODOya Demirci
Oya Demirci
IYİlker Kemal Yücel
İlker Kemal Yücel

20 June 2025 in Acta Diabetologica
Verified
Journal Article
Closed access
PDF file
MGMurad Gezer
Murad Gezer
ÜTÜmit Taşdemir
Ümit Taşdemir
ÖEÖmer Gökhan Eyisoy
Ömer Gökhan Eyisoy
SYSevdenur Yiğit
Sevdenur Yiğit
MÖMucize Eriç Özdemir
Mucize Eriç Özdemir
ODOya Demirci
Oya Demirci

3 October 2025
Verified
Book Chapter
Open access
PDF file
MGMurad Gezer
Murad Gezer
Preterm doğum, neonatal mortalite ve morbiditenin başlıca nedenlerinden biridir ve hayatta kalan bebeklerde serebral palsi (SP) riski belirgin şekilde artmaktadır. SP için kesin tedavi bulunmadığından, antenatal dönemde uygulanabilecek koruyucu yaklaşımlar kritik önemdedir. Bu kapsamda magnezyum sülfatın preterm doğum riski taşıyan gebelerde fetal nöroprotektif potansiyeli çok sayıda randomize kontrollü çalışma ve meta-analiz ile araştırılmıştır. ACTOMgSO₄, BEAM, PREMAG ve MAGENTA çalışmaları, farklı doz ve protokollerle uygulanmış olup özellikle BEAM çalışmasında orta-şiddetli SP insidansında anlamlı azalma gösterilmiştir. 2024 Cochrane meta-analizi, magnezyum sülfatın ölüm veya SP riskini iki yaşına kadar azalttığını, ancak uzun dönem takiplerde etkinin istatistiksel olarak anlamlı olmadığını bildirmiştir. Klinik uygulamada, 24–32. gebelik haftaları arasında, doğumun 24 saat içinde gerçekleşme olasılığı yüksek gebelikler tedavi için uygun adaylardır. Uygulama genellikle 6 g yükleme ve 2 g/saat idame şeklinde yapılmakta, maksimum 24 saat ile sınırlandırılmaktadır. Kontrendikasyonlar arasında myastenia gravis öne çıkarken, böbrek fonksiyon bozukluğunda doz ayarlaması gerekmektedir. Antenatal kortikosteroidlerle kombine kullanım, özellikle aşırı preterm olgularda mortalite ve majör nörogelişimsel bozukluk riskini azaltıcı sinerjik etki sunmaktadır.

11 November 2025 in Journal of Obstetrics and Gynaecology Research
Verified
Journal Article
Closed access
MGMurad Gezer
Murad Gezer
EYElif Yılmaz
Elif Yılmaz
HGHalise Hande Gezer
Halise Hande Gezer
TKTuncay Küçüközkan
Tuncay Küçüközkan